JACC: Basic to Translational Science (Apr 2017)

Cardiac Myosin Binding Protein-C Autoantibodies Are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome

  • Thomas L. Lynch, IVPhD,
  • Diederik W.D. Kuster, PhD,
  • Beverly Gonzalez, ScM,
  • Neelam Balasubramanian, BA,
  • Nandini Nair MD, PhD,
  • Sharlene Day, PhD,
  • Jenna E. Calvino, BA,
  • Yanli Tan, RN,
  • Christoph Liebetrau, MD,
  • Christian Troidl, PhD,
  • Christian W. Hamm, MD,
  • Ahmet Güçlü, MD,
  • Barbara McDonough, RN,
  • Ali J. Marian, MD,
  • Jolanda van der Velden, PhD,
  • Christine E. Seidman, MD,
  • Gordon S. Huggins, MD,
  • Sakthivel Sadayappan, PhD

Journal volume & issue
Vol. 2, no. 2
pp. 122 – 131

Abstract

Read online

Summary: The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in cardiovascular disease patients. Importantly, cMyBP-C-AAbs were significantly detected in acute coronary syndrome patient sera upon arrival to the emergency department, particularly in ST-segment elevation myocardial infarction patients. Patients positive for cMyBP-C-AAbs had reduced left ventricular ejection fraction and elevated levels of clinical biomarkers of myocardial infarction. We conclude that cMyBP-C-AAbs may serve as early predictive indicators of deteriorating cardiac function and patient outcome in acute coronary syndrome patients prior to the infarction. Key Words: acute myocardial infarction, autoantibodies, cardiac myosin binding protein-c, cardiomyopathy